International Conference on Emerging Infectious Diseases

Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon

Retrieved on: 
Friday, October 27, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, AD, Neuroimaging, Houston Methodist Hospital, COYA, International Conference on Emerging Infectious Diseases, Biomarker, Assistant, LD, Neurology, Conference, Bill & Melinda Gates Foundation, Cerebrospinal fluid, Blood, Weill Cornell Medicine, Safety, Melinda French Gates, Therapy, Patient, Pharmaceutical industry

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced that Dr. Alireza Faridar, Assistant Professor of Neurology at Houston Methodist and Weill Cornell Medical College, will give an oral presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease held in Lisbon, Portugal between March 5-9, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced that Dr. Alireza Faridar, Assistant Professor of Neurology at Houston Methodist and Weill Cornell Medical College, will give an oral presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease held in Lisbon, Portugal between March 5-9, 2024.
  • Details and Registration for the conference are found here.
  • Topline results of this study are anticipated to be reported in the first half of 2024.
  • The study is funded by the Gates Foundation and the Alzheimer’s Association.

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

Retrieved on: 
Wednesday, October 25, 2023
Headache, Neuron, Biogen, Biomarker, ASO, CSF, International Conference on Emerging Infectious Diseases, Pathology, Conference, MAPT, BIIB, PET, LTE, Disease, Cancer, Messenger, MMSE, FAQ, Safety, Ionis, Pain, Patient, Back pain, Cognition, Pharmaceutical industry, Dietary supplement, Medical imaging

First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.

Key Points: 
  • First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.
  • CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD).
  • The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.
  • The favorable trends suggest a potential link between a reduction in tau PET pathology and clinical outcomes.

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Retrieved on: 
Wednesday, October 18, 2023
International Conference on Emerging Infectious Diseases, Biomarker, Gastroenterology, Colorectal cancer, Conference, CRC, Messenger, Cancer, Gene expression, Vaccine

BERKELEY, Calif. and MAINZ, Germany, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer is presenting its groundbreaking results of its ColoFuture Study. Originally scheduled for presentation by Dr Moritz Eidens, the Company’s Chief Scientific Officer, to assembled academics as part of a poster session at the 4th International Conference on Gastroenterology in Paris, the event has since been rescheduled from October to December. In consultation with the Conference leadership, Mainz Biomed has opted to release the eagerly anticipated ColoFuture results in line with the original conference schedule.

Key Points: 
  • Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CRC
    BERKELEY, Calif. and MAINZ, Germany, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer is presenting its groundbreaking results of its ColoFuture Study.
  • Originally scheduled for presentation by Dr Moritz Eidens, the Company’s Chief Scientific Officer, to assembled academics as part of a poster session at the 4th International Conference on Gastroenterology in Paris , the event has since been rescheduled from October to December.
  • In consultation with the Conference leadership, Mainz Biomed has opted to release the eagerly anticipated ColoFuture results in line with the original conference schedule.
  • The ColoFuture study was a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe and in select international territories.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Retrieved on: 
Monday, October 16, 2023
TSX, Abstract, TUS, International Conference on Emerging Infectious Diseases, Treatment, Trial of the century, Apoptosis, European School, AML, VEN, RSK, Acute myeloid leukemia, SAN, SYK, KIT, FLT3, Conference, Patient, Pharmaceutical industry, Biology

Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.

Key Points: 
  • Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.
  • The posters accepted for presentation are listed below and can be viewed beginning October 29, 2023, on site at the ESH poster exhibit hall and online on the Aptose website here .
  • Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.
  • We investigated the effects of TUS on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells.

Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
Abstract (summary), AACR, UNO, International Conference on Emerging Infectious Diseases, Research, Conference, Treatment, Rare-earth element, Paint, Mobile phone, Cancer

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts.

Key Points: 
  • GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts.
  • Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U.S.
  • ET.
  • Details of the Company’s poster presentations are as follows:

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, August 10, 2023
PK, BIO, Obesity, Therapy, ATS, LPAR1, Pharmacokinetics, Ted, T2DM, Trial of the century, Type, GPCR, American Thoracic Society, International Conference on Emerging Infectious Diseases, Investment, Biotechnology Innovation Organization, Annual general meeting, Overweight, MAD, Research, American Diabetes Association, ADA, Conference, Safety, D, Pharmaceutical industry, Cryptocurrency

SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements.

Key Points: 
  • Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290
    SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements.
  • Topline data are expected to be announced in latter half of fourth quarter 2023.
  • Structure Therapeutics presented data from the Phase 1 single ascending dose clinical study and preclinical data of GSBR-1290 at the 2023 American Diabetes Association (ADA) Annual Meeting in June 2023.
  • R&D Expenses: Research and development expenses were $19.4 million for the quarter ended June 30, 2023, as compared to $10.2 million for the same period in 2022.

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, July 13, 2023
CLL, Lymphoma, Gilead Sciences, AACR, Central nervous system, Chronic lymphocytic leukemia, Information technology, Lymphoid leukemia, DLBCL, ICML, Calendar, Disclosure, Clinical trial, American Association for Cancer Research, Research, BTK, CNS, Casitas, American Chemical Society, International Conference on Emerging Infectious Diseases, Patient, Investment, Mantle cell lymphoma, SAN, Paclitaxel, Bone marrow, MCL, Neoplasm, FDA, Therapy, IND, Conference, Rheumatoid arthritis, Inflammation, Pharmaceutical industry, Cryptocurrency, Vaccine, IRAK4, Sanofi

SAN FRANCISCO, July 13, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update.

Key Points: 
  • Nurix also presented preclinical data demonstrating the potential utility of NX-5948 in addressing the unmet need in patients with central nervous system (CNS) lymphoma.
  • Nurix anticipates presenting additional clinical results from this ongoing trial in the second half of 2023.
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in the second half of 2023 based on emerging clinical data and feedback from the FDA.
  • Cash, cash equivalents and marketable securities was $308.6 million as of May 31, 2023, compared to $325.6 million as of February 28, 2023.

Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)

Retrieved on: 
Tuesday, July 11, 2023
Managed Care, Research, Pharmaceutical, Mental Health, Hospitals, Genetics, Clinical Trials, Science, Cardiology, Neurology, Biotechnology, Health, Other Science, 3R, Therapy, DSM-IV codes, SAD, Patient, Participation, International Conference on Emerging Infectious Diseases, Donanemab, AD, Conference, Pharmaceutical industry, Medical imaging, R2, MD

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.
  • Participation includes three posters highlighting the company’s next generation therapies for Alzheimer’s disease and a Prothena sponsored symposium.
  • Poster #82687, available to view starting Sunday, July 16, 2023
    Prothena will present an encore poster presentation of data originally presented at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) on preclinical data from the PRX012 program comparing a PRX012-surrogate1 (PRX012s) with lecanemab and donanemab.
  • Poster #74811, available to view starting Sunday, July 16, 2023
    On Tuesday, July 18 from 5:45-7:45 PM CEST, Prothena will host an industry sponsored symposium titled “The Voice of the Patient with AD: What Progress in AD Treatment Means to People Living with the Disease”.

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

Retrieved on: 
Saturday, June 17, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lymphoma, Bristol Myers Squibb, ICML, Disclosure, Clinical trial, NHL, BMY, NYSE, CAR, International Conference on Emerging Infectious Diseases, Patient, Cell, MCL, Conference, ORR, Pharmaceutical industry, Veterinary medicine, Lisocabtagene maraleucel

These data were presented in late-breaking oral presentations at the 2023 International Conference on Malignant Lymphoma (ICML) on Saturday, June 17.

Key Points: 
  • These data were presented in late-breaking oral presentations at the 2023 International Conference on Malignant Lymphoma (ICML) on Saturday, June 17.
  • Bristol Myers Squibb thanks the patients and investigators involved in the TRANSCEND clinical trials.
  • Patients received treatment with Breyanzi at a target dose of 100 x 106 CAR-positive viable T cells.
  • Responses were durable with a median duration of response not reached at a median follow-up of 16.6 months.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.